Samsung Biologics Appoints John Rim as New CEO and President

[Asia Economy Reporter Cho Hyun-ui] "Over the next 10 years, we will achieve global number one status in all business sectors including Contract Manufacturing Organization (CMO), Contract Development Organization (CDO), and Contract Research Organization (CRO)."

John Lim, the newly appointed CEO of Samsung Biologics, stated this in his inaugural speech after being appointed as CEO at the board meeting on the 16th. He added, "In the long term, let us leap forward as a global bio-pharmaceutical company operating major businesses in the biopharmaceutical industry."

Samsung Biologics is currently the world's number one CMO company for biopharmaceuticals. Lim said, "We will continue to maintain our number one position in CMO through bold and proactive investments, while also elevating the technology and capabilities of CDO and CRO to the global top level."

Lim holds a master's degree in Chemical Engineering from Stanford University and an MBA from Northwestern University. He is a global bio-pharmaceutical expert who has held positions such as head of production, sales, development, and Chief Financial Officer (CFO) at multinational pharmaceutical companies Roche and Genentech. He joined Samsung Biologics in September 2018 and oversaw the operation of the world's largest biopharmaceutical plant, the 3rd plant.

Lim said, "We will inherit the innovative will and spirit of challenge that led Samsung Biologics' growth over the past 10 years, strengthen collaboration, and open a new era for Samsung Biologics to leap toward the world’s top tier."

This content was produced with the assistance of AI translation services.